PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 136 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2015. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,243,000 | +2.4% | 147,303 | +6.2% | 0.52% | +22.2% |
Q4 2019 | $1,214,000 | -37.7% | 138,729 | -20.6% | 0.43% | -42.5% |
Q3 2019 | $1,949,000 | +20.7% | 174,641 | +37.5% | 0.74% | +25.5% |
Q2 2019 | $1,615,000 | +3.7% | 127,029 | +71.9% | 0.59% | -14.2% |
Q1 2019 | $1,558,000 | 0.0% | 73,876 | 0.0% | 0.69% | +3.6% |
Q4 2018 | $1,558,000 | -13.3% | 73,876 | +88.4% | 0.67% | +8.1% |
Q3 2018 | $1,796,000 | -12.2% | 39,209 | +8.0% | 0.62% | -18.5% |
Q2 2018 | $2,045,000 | +14.6% | 36,297 | +38.4% | 0.76% | +3.0% |
Q1 2018 | $1,785,000 | +21.1% | 26,229 | +75.9% | 0.73% | +15.2% |
Q4 2017 | $1,474,000 | -17.4% | 14,909 | 0.0% | 0.64% | -20.1% |
Q3 2017 | $1,785,000 | +8.2% | 14,909 | -21.0% | 0.80% | +6.1% |
Q2 2017 | $1,650,000 | +69.9% | 18,874 | -27.7% | 0.75% | +94.1% |
Q1 2017 | $971,000 | +767.0% | 26,105 | +1649.7% | 0.39% | +578.9% |
Q3 2015 | $112,000 | -35.6% | 1,492 | 0.0% | 0.06% | -27.8% |
Q2 2015 | $174,000 | -50.6% | 1,492 | 0.0% | 0.08% | -50.9% |
Q1 2015 | $352,000 | – | 1,492 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |